La maladie de Parkinson au Canada (serveur d'exploration) - Curation (Ncbi)

Index « Keywords » - entrée « Antiparkinson Agents (pharmacology) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antiparkinson Agents (pharmacokinetics) < Antiparkinson Agents (pharmacology) < Antiparkinson Agents (therapeutic use)  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 45.
[0-20] [0 - 20][0 - 45][20-40]
Ident.Authors (with country if any)Title
000095 (2000) F. Calon [Canada] ; M. Morissette ; M. Goulet ; R. Grondin ; P J Blanchet ; P J Bédard ; T. Di Paolo125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
000117 (2000) M. Goulet [Canada] ; R. Grondin ; M. Morissette ; S. Maltais ; P. Falardeau ; P J Bédard ; T. Di PaoloRegulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys.
000125 (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
000128 (2000) J S Frank [Canada] ; F B Horak ; J. NuttCentrally initiated postural adjustments in parkinsonian patients on and off levodopa.
000173 (2001) G A Metz [Canada] ; T. Farr ; M. Ballermann ; I Q WhishawChronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
000219 (2002) J F Gagnon [Canada] ; J. Montplaisir ; M A Bédard[Rapid-eye-movement sleep disorders in Parkinson's disease].
000256 (2002) Raúl De La Fuente-Fernández [Canada] ; Anthony G. Phillips ; Mariangela Zamburlini ; Vesna Sossi ; Donald B. Calne ; Thomas J. Ruth ; A Jon StoesslDopamine release in human ventral striatum and expectation of reward.
000307 (2003) Michael Schulzer [Canada] ; Edwin Mak ; Susan M. CalneThe psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease.
000337 (1992) B. Gomez-Mancilla [Canada] ; P J BédardEffect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
000447 (2004) Tom H. Johnston [Canada] ; Jonathan M. BrotchieDrugs in development for Parkinson's disease.
000674 (2006) Michel St-Hilaire [Canada] ; Emmanuelle Bourhis ; Daniel Lévesque ; Claude RouillardImpaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
000749 (2007) Brigitte Stemmer [Canada] ; Sidney J. Segalowitz ; Jane Dywan ; Michel Panisset ; Calvin MelmedThe error negativity in nonmedicated and medicated patients with Parkinson's disease.
000794 (2007) Joseph S. Tauskela [Canada]MitoQ--a mitochondria-targeted antioxidant.
000800 (2007) Vicki Oldfield [États-Unis] ; Gillian M. Keating ; Caroline M. PerryRasagiline: a review of its use in the management of Parkinson's disease.
000890 (2008) Jon Stoessl [Canada]Potential therapeutic targets for Parkinson's disease.
000950 (2009) S J Palmer [Canada] ; L. Eigenraam ; T. Hoque ; R G Mccaig ; A. Troiano ; M J MckeownLevodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
000981 (2009) D. Mongeon [Canada] ; P. Blanchet ; J. MessierImpact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
000A28 (2009) Shen-Yang Lim [Canada] ; Susan H. Fox ; Anthony E. LangOverview of the extranigral aspects of Parkinson disease.
000A90 (2009) Moran Weinberger [Canada] ; William D. Hutchison ; Jonathan O. DostrovskyPathological subthalamic nucleus oscillations in PD: can they be the cause of bradykinesia and akinesia?
000B11 (2010) Bernard Ng [Canada] ; Samantha Palmer ; Rafeef Abugharbieh ; Martin J. MckeownFocusing effects of L-dopa in Parkinson's disease.
000C12 (2010) Bazoumana Ouattara [Canada] ; Fabrizio Gasparini ; Marc Morissette ; Laurent Grégoire ; Pershia Samadi ; Baltazar Gomez-Mancilla ; Thérèse Di PaoloEffect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Antiparkinson Agents (pharmacology)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Antiparkinson Agents (pharmacology)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antiparkinson Agents (pharmacology)
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022